-
公开(公告)号：US20240344027A1
公开(公告)日：2024-10-17
申请号：US18587729
申请日：2024-02-26
IPC分类号： C12N5/0789 , A61K31/436 , A61K31/445 , A61K35/12 , A61K35/17 , A61K35/28 , A61K39/00 , A61P35/02 , A61P37/06 , C12N5/0783
CPC分类号： C12N5/0647 , A61K31/436 , A61K31/445 , A61K35/17 , A61K35/28 , A61K39/001 , A61P35/02 , A61P37/06 , C12N5/0637 , A61K2035/122 , C12N2506/11
摘要： The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.
-
公开(公告)号：US11952588B2
公开(公告)日：2024-04-09
申请号：US16967375
申请日：2019-02-07
发明人： Everett H. Meyer , Robert S. Negrin
IPC分类号： A61K35/17 , A61K31/436 , A61K31/445 , A61K35/28 , A61K39/00 , A61P35/02 , A61P37/06 , C12N5/0783 , C12N5/0789 , A61K35/12
CPC分类号： C12N5/0647 , A61K31/436 , A61K31/445 , A61K35/17 , A61K35/28 , A61K39/001 , A61P35/02 , A61P37/06 , C12N5/0637 , A61K2035/122 , C12N2506/11
摘要： The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.
-
公开(公告)号：US11447747B2
公开(公告)日：2022-09-20
申请号：US17031213
申请日：2020-09-24
IPC分类号： C12N5/0789 , A61K35/17 , A61P37/06 , A61K31/445 , A61K39/00 , C12N5/0783 , A61P35/02 , A61K31/436 , A61K35/28 , A61K35/12
摘要： The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.
-
公开(公告)号：US20210030797A1
公开(公告)日：2021-02-04
申请号：US16967375
申请日：2019-02-07
IPC分类号： A61K35/17 , A61K35/28 , A61K31/436 , A61P37/06 , A61P35/02
摘要： The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.
-
公开(公告)号：US20210015862A1
公开(公告)日：2021-01-21
申请号：US17031213
申请日：2020-09-24
IPC分类号： A61K35/17 , A61K35/28 , A61K31/436 , A61P37/06 , A61P35/02
摘要： The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.
-
公开(公告)号：US20210002613A1
公开(公告)日：2021-01-07
申请号：US17031187
申请日：2020-09-24
IPC分类号： C12N5/0789 , A61P37/06 , A61K31/445 , C12N5/0783 , A61K39/00
摘要： The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.024 秒)
